Import Alert 55-05

f share (https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/cms_ia/importalert_1126.html)

Y TWEET (HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=IMPORT ALERT 55-05&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/CMS_IA/IMPORTALERT_1126.HTML)

<u>+</u>

■ EMAIL (MAILTO:?SUBJECT=IMPORT ALERT 55-05&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/CMS_IA/IMPORTALERT_1126.HTML)

(Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public).

Import Alert # 55-05

Published Date: 03/27/2018

Type: DWPE

Import Alert Name:

DETENTION WITHOUT PHYSICAL EXAMINATION OF FINISHED DOSAGE DRUG PRODUCTS, ACTIVE PHARMACEUTICAL INGREDIENTS AND INACTIVE INGREDIENTS FOR POTENTIALLY HAZARDOUS MICROBIOLOGICAL CONTAMINATION

Reason for Alert:

Due to similar issues, the information in IA #55-04 is being incorporated into this alert and will henceforth be discontinued.

FDA collects and analyzes samples of finished dosage products, active pharmaceutical ingredients and inactive ingredients considered at risk for potentially hazardous microbial contamination that pose a health risk. Detention without physical examination may be appropriate when sample results reveal a potential health risk.

Guidance:

Districts may detain, without physical examination, the specified

products from the firms listed in the Red List of this Import Alert.

Districts should recommend detention without physical examination under this import alert when analytical results reveal the presence of potentially hazardous microbial contamination for pharmaceutical use. Forward background information, including analytical worksheets, product labeling and entry documents, to the Division of Import Operations (DIO). DIO will coordinate with CDER for concurrence.

In order for a firm to be removed from detention without physical examination, information should be provided to FDA to adequately demonstrate that the manufacturer has resolved the conditions that gave rise to the appearance of the violation, so that the agency will have confidence that future entries will be in compliance. This may include a letter detailing its corrective actions, accompanied by documentation.

For guidance on removal from detention without physical examination,

refer to FDA s Regulatory Procedures Manual, Chapter 9, "Detention

Without Phy	vsical	Examinati	on (DWPF	۱ "
vvitilout i ii	y SiGai i	∟∧aıııııaıı	UII (DVVIL	<i>)</i> .

If a firm, shipper or importer wishes to request removal from detention without physical examination, they should forward information supporting their request to FDA at the following address:

Food and Drug Administration

Division of Import Operations

12420 Parklawn Drive, ELEM-3109

Rockville, MD 20857

3/28/2018

Or via email: Importalerts2@fda.hhs.gov

For questions or issues involving import operations, contact the Division of Import Operations at (301) 796-0356.

For questions or issues concerning science, science policy, analysis, preparation, or analytical methodology, contact the Office of Regulatory Science at (301) 796-6600.

Product Description:

CDER regulated finished dosage form drug products, active pharmaceutical ingredients, and inactive ingredients

Charge:

The article is subject to refusal of admission pursuant to section 801(a)(3) of the FFD&CA in that the article contains potentially hazardous, or otherwise objectionable in light of intended use, microbial adulteration and therefore consists in part of a filthy substance. [Adulteration, Section 501(a)(1)].

OASIS CHARGE CODE: FILTH

AND/OR

The article is subject to refusal of admission pursuant to section 801(a)(1) in that the article appears to have been manufactured, processed, or packed under insanitary conditions □

OASIS CHARGE CODE: MFR INSAN

AND/OR

The article is subject to refusal of admission pursuant to section 801(a)(3) in that the article appears to have been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health [Adulteration, Section 501(a)(2)(A)].□

OASIS CHARGE CODE: INSANITARY

AND/OR

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears the methods used in, or the facilities or controls used for, the manufacture, processing, packing, or holding of the article do not appear to conform to or are not operated or administered in conformity with current

good manufacturing practices. [Adulteration, Section 501(a)(2)(B)].□

OASIS CHARGE CODE: DRUG GMPs

PROBLEM: Adulteration

List of firms and their products subject to Detention without Physical Examination (DWPE) under this Import Alert (a.k.a. Red List)

CANADA

Delta Pharma Inc. Date Published: 05/22/2013

1655 Rte Transcanadienne , Dorval, Quebec CANADA 66 V - - 99 Miscellaneous Patent Medicines, Etc.

Desc: Face Values for Baby Healing Ointment

INDIA

Contacare Ophthalmics & Diagnostics

310b Village Sim, Block No, Dabhasa, Gujarat INDIA

55 R P - 14 Hydroxypropyl Methylcellulose (Pharmaceutic Necessity - Suspending Agent), Pharma Necess Date Published: 08/23/2017

Desc: Hydroxypropyl Methyl Cellulose

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

55 R P - 55 Sodium Chloride (Pharmaceutic Necessity - Tonicity Agent), Pharma Necess Date Published: 08/23/2017

Desc: Sodium Chloride

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

63 X C P 69 lopydol (Diagnostic Aid) (Drugs), Human - Rx/Single Ingredient, Small Volume Parenteral <100ml

Desc: Lopydol

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

63 X - - 12 Fluorescein Sodium (Diagnostic Aid) (Drugs)

Date Published: 08/23/2017

Desc: Fluorescein Sodium

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

63 X - - 99 Diagostic Aid (Drugs) N.E.C. Date Published: 08/23/2017

Date Published: 05/22/2013

Date Published: 08/23/2017

Date Published: 08/23/2017

Desc: Sodium Chloride

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

65 R A K 19 Sodium Chloride (Replenisher), Human - Non/Rx Single Ingredient, Sterile Liquid Date Published: 08/23/2017

Desc: Sodium Chloride

Notes: DWPE applies to all aseptically processed drugs manufactured or shipped by Contacare Ophthalmics & Diagnostics.

KOREA, REPUBLIC OF (SOUTH)

Neo Vision Co., Ltd. Date Published: 12/13/2016 93 Jeungsin-ro, Iceon-si, Gyeonggi-do KOREA, REPUBLIC OF (SOUTH) 55 - - - - Pharm Necess & Ctnr For Drug/Bio Date Published: 12/13/2016 Notes: All drugs and drug products 56 - - - - Antibiotics (Human/Animal) Date Published: 12/13/2016 Notes: All drugs and drug products 60 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 61 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 62 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 63 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 64 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 65 - - - -- Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products 66 - - - - Human and Animal Drugs Date Published: 12/13/2016 Notes: All drugs and drug products

MEXICO

Brady Mexico S De RL de CV Date Published : 08/26/2016

Guerrero Negro, Tijuana, Bc MEXICO

55 R - - 55 Sodium Chloride (Pharmaceutic Necessity - Tonicity Agent)

Desc: Eyesaline Eyewash

Notes:

55 R - - 56 Ethyl Oleate (Pharmaceutic Necessity - Vehicle)

Date Published: 08/26/2016

Desc: Eyesaline Eyewash

Notes:

65 F - - 06 Water, Purified (Eyewash)

Date Published: 08/26/2016

Desc: Eyesaline Eyewash

Notes:

65 R - - 12 Potassic Saline (Injection) (Replenisher)

Date Published: 08/26/2016

Desc: Eyesaline Eyewash

Notes:

Industria Farmaceutica Andromaco S.A. de C.V. Date Published : 03/27/2018

Calle Eje 3 Norte No. 202, Parque Industrial Toluca 2000, Toluca, Mexico MEXICO

55 - - - - Pharm Necess & Ctnr For Drug/Bio Date Published: 03/27/2018

Date Published: 08/26/2016

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

56 - - - - Antibiotics (Human/Animal)

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

60 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andremaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

61 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

62 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

63 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andremaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

64 - - - -- Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

65 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andromaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

66 - - - - Human and Animal Drugs

Date Published: 03/27/2018

Notes: All Drug and Drug Products; A shipment of "Pasta de Lassar Andremaco" Zinc Oxide (Skin Protectant) Diaper Rash Cream was found to contain potentially hazardous microbiological contamination. CDER recommends to place Industria Farmaceutica Andromaco S.A. de C.V. and all drug products manufactured by this firm on the Red List of IA #55-05 to protect the public health.

UNITED STATES

Sperian Eye & Face Protection, Inc.

825 E Business Highway 151 , Platteville, WI 53818-3763 UNITED STATES

55 R - - 55 Sodium Chloride (Pharmaceutic Necessity - Tonicity Agent)

Desc: Eyesaline Eyewash

55 R - - 56 Ethyl Oleate (Pharmaceutic Necessity - Vehicle)

Desc: Eyesaline Eyewash

65 F - - 06 Water, Purified (Eyewash)

Desc: Eyesaline Eyewash

65 R - - 12 Potassic Saline (Injection) (Replenisher)

Desc: Eyesaline Eyewash

Date Published : 08/26/2016

Date Published: 08/26/2016

Date 1 abilioned: 00/20/2010

Date Published: 08/26/2016

Date Published: 08/26/2016

Date Published: 08/26/2016